Michael Girschikofsky
Overview
Explore the profile of Michael Girschikofsky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
1437
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Egle A, Melchardt T, Obrtlikova P, Smolej L, Kozak T, Steurer M, et al.
Cancer Med
. 2019 Mar;
8(4):1401-1405.
PMID: 30888118
No data are available regarding obesity and outcome in Chronic Lymphocytic Leukemia (CLL). We analyzed 263 patients from the AGMT CLL-8a Mabtenance trial for the impact of obesity. The trial...
12.
Schlenk R, Weber D, Fiedler W, Salih H, Wulf G, Salwender H, et al.
Blood
. 2018 Dec;
133(8):840-851.
PMID: 30563875
Patients with acute myeloid leukemia (AML) and a internal tandem duplication (ITD) have poor outcomes to current treatment. A phase 2 hypothesis-generating trial was conducted to determine whether the addition...
13.
Egle A, Steurer M, Melchardt T, Weiss L, Gassner F, Zaborsky N, et al.
Ann Hematol
. 2018 Jun;
97(9):1745.
PMID: 29934835
The original version of this article contained a mistake. The name of Tanja Nicole Hartman should have been Tanja Nicole Hartmann. The original article has been corrected.
14.
Egle A, Steurer M, Melchardt T, Weiss L, Gassner F, Zaborsky N, et al.
Ann Hematol
. 2018 Jun;
97(10):1825-1839.
PMID: 29862437
Despite recent advances, chemoimmunotherapy remains a standard for fit previously untreated chronic lymphocytic leukaemia patients. Lenalidomide had activity in early monotherapy trials, but tumour lysis and flare proved major obstacles...
15.
Paschka P, Schlenk R, Weber D, Benner A, Bullinger L, Heuser M, et al.
Leukemia
. 2018 May;
32(7):1621-1630.
PMID: 29720733
In this phase Ib/IIa study (ClinicalTrials.gov Identifier: NCT00850382) of the German-Austrian AML Study Group (AMLSG) the multikinase inhibitor dasatinib was added to intensive induction and consolidation chemotherapy and administered as...
16.
Sperr W, Herndlhofer S, Gleixner K, Girschikofsky M, Weltermann A, Machherndl-Spandl S, et al.
Am J Hematol
. 2017 Jul;
92(10):E567-E574.
PMID: 28699225
The aim of this study was to evaluate the efficacy and feasibility of intensified consolidation therapy employing fludarabine and ARA-C in cycle 1 and intermediate-dose ARA-C (IDAC) in cycles 2...
17.
Pleyer L, Dohner H, Dombret H, Seymour J, Schuh A, Beach C, et al.
Int J Mol Sci
. 2017 Feb;
18(2).
PMID: 28212292
We recently published a clinically-meaningful improvement in median overall survival (OS) for patients with acute myeloid leukaemia (AML), >30% bone marrow (BM) blasts and white blood cell (WBC) count ≤15...
18.
Zebisch A, Lal R, Muller M, Lind K, Kashofer K, Girschikofsky M, et al.
Blood
. 2016 Sep;
128(18):2270-2272.
PMID: 27621308
No abstract available.
19.
Greil R, Obrtlikova P, Smolej L, Kozak T, Steurer M, Andel J, et al.
Lancet Haematol
. 2016 Jul;
3(7):e317-29.
PMID: 27374465
Background: In many patients with chronic lymphocytic leukaemia requiring treatment, induction therapy with rituximab plus chemotherapy improves outcomes compared with chemotherapy alone. In this study we aimed to investigate the...
20.
Pleyer L, Burgstaller S, Stauder R, Girschikofsky M, Sill H, Schlick K, et al.
J Hematol Oncol
. 2016 Apr;
9:39.
PMID: 27084507
Background: The MDS-IWG and NCCN currently endorse both FAB and WHO classifications of MDS and AML, thus allowing patients with 20-30 % bone marrow blasts (AML20-30, formerly MDS-RAEB-t) to be...